The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Open accessAbstract
The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes and integrate multidimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively. Gene signatures of normal brain cell types show a strong relationship between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype, with the greatest benefit in the Classical subtype and no benefit in the Proneural subtype. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“High-throughput genomic, epigenomic, and transcriptomic profiling of glioblastoma cells revealed three main subtypes harboring distinct molecular and phenotypic landscapes that affect response to the therapy and clinical outcome: mesenchymal, proneural, and classical subtypes.96,97,98,99,100”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, IDH mutant gliomas strongly express PDGFRA (Fig. 2b), and share the proneural transcriptional program characteristic of PDGFRA-amplified tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of p53 mutations differs in the different GBM molecular subtypes (proneural, mesenchymal, neural and classical) (54%, 32%, 21% and 0%, respectively) [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crucially, the levels of miR-128-3p forms can also differ depending on the genetic and molecular background, as they correlated with the glioblastoma subtypes, with the most reduced expression in the most aggressive mesenchymal one.96,113”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, upregulation of PDGFRA, platelet-derived growth factor receptor alpha, is a hallmark of the proneural subtype [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
In the citing paper
“While glioblastoma is the most common malignant primary brain tumor26–28, it is still classified as a “rare” disease, as its incidence rate (i.e., 3/100,000 people) is substantially lower than the rare disease definition rate (i.e., <10/100,000 people)24.”
From Federated learning enables big data for rare cancer boundary detection (2022) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silhouettes: A graphical aid to the interpretation and validation of cluster analysis
Rousseeuw, P. J. (1987) · Journal of Computational and Applied Mathematics · doi:10.1016/0377-0427(87)90125-7 · Cited by 21,392
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F. Z., Miled, S. B., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,785
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,837
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citation
Flagged first, then by citations
2 of the 52 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 801–900 of 1,022
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes
Duncan, C. G., Killela, P. J., Payne, C. A., Lampson, B. L., Chen, W., Liu, J., Solomon, D. A., Waldman, T. A., Towers, A. J., Gregory, S. G., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.137 · Cited by 114
Yang, P., Cai, J., Yan, W., Zhang, W., Wang, Y., Chen, B., Li, G., Li, S., Wu, C., Yao, K., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now021 · Cited by 116
A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma
Guo, G., Gong, K., Ali, S., Ali, N., Shallwani, S., Hatanpaa, K. J., Pan, E., Mickey, B., Burma, S., Wang, D. H., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4584 · Cited by 116
Self-citationTejero, R., Huang, Y., Katsyv, I., Kluge, M., Lin, J., Tomé-García, J., Daviaud, N., Wang, Y., Zhang, B., Tsankova, N. M., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.064 · Cited by 117
Xiao, Y., Kim, D., Dura, B., Zhang, K., Yan, R., Li, H., Han, E., Ip, J., Zou, P., Liu, J., et al. (2019) · Advanced Science · doi:10.1002/advs.201801531 · Cited by 115
Prognosis of patients with multifocal glioblastoma: a case-control study
Patil, C. G., Yi, A., Elramsisy, A., Hu, J. L., Mukherjee, D. R., Irvin, D. K., Yu, J. S., Bannykh, S., Black, K. L., & Nuño, M. (2012) · Journal of neurosurgery · doi:10.3171/2012.7.jns12147 · Cited by 113
Genetic architecture of cancer and other complex diseases: lessons learned and future directions
Hindorff, L. A., Gillanders, E. M., & Manolio, T. A. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr056 · Cited by 115
Abou‐El‐Ardat, K., Seifert, M., Becker, K., Eisenreich, S., Lehmann, M., Hackmann, K., Rump, A., Meijer, G. A., Carvalho, B. G., Temme, A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now231 · Cited by 114
Malric, L., Monferran, S., Gilhodes, J., Boyrie, S., Dahan, P., Skuli, N., Sesen, J., Filleron, T., Kowalski‐Chauvel, A., Moyal, E. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20372 · Cited by 115
Mutant IDH1 Promotes Glioma Formation In Vivo
Philip, B., Yu, D. X., Silvis, M. R., Shin, C., Robinson, J. P., Robinson, G. L., Welker, A., Angel, S. N., Tripp, S. R., Sonnen, J. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.133 · Cited by 112
Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide
López-Valero, I., Sáiz-Ladera, C., Torres, S., Hernández‐Tiedra, S., García-Taboada, E., Rodríguez-Fornés, F., Barba‐Aliaga, M., Dávila, D., Salvador, N., Guzmán, M., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.007 · Cited by 114
Survivorship in adults with malignant brain and other central nervous system tumor from 2000–2014
Gittleman, H. R., Boscia, A. L., Ostrom, Q. T., Truitt, G., Fritz, Y., Kruchko, C. A., & Barnholtz‐Sloan, J. S. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy090 · Cited by 113
CTLA-4 correlates with immune and clinical characteristics of glioma
Liu, F., Huang, J., Liu, X., Cheng, Q., Luo, C., & Liu, Z. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1085-6 · Cited by 115
Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy
Park, J. H., & Lee, H. K. (2022) · Cancers · doi:10.3390/cancers14051176 · Cited by 117
Pan-cancer proteogenomics connects oncogenic drivers to functional states
Li, Y., Porta‐Pardo, E., Tokheim, C. J., Bailey, M. H., Yaron, T. M., Stathias, V., Geffen, Y., Imbach, K. J., Cao, S., Anand, S. K., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.014 · Cited by 124
Self-citationJin, G., Reitman, Z. J., Spasojevic, I., Batinic-Haberle, I., Yang, J., Schmidt-Kittler, O., Bigner, D. D., & Yan, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016812 · Cited by 112
p120-catenin-dependent collective brain infiltration by glioma cell networks
Gritsenko, P. G., Atlasy, N., Dieteren, C. E. J., Navis, A. C., Venhuizen, J.-H., Veelken, C., Schubert, D., Acker-Palmer, A., Westerman, B. A., Wurdinger, T., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-019-0443-x · Cited by 112
Hominoid-specific enzyme GLUD2 promotes growth of IDH1 R132H glioma
Chen, R., Nishimura, M. C., Kharbanda, S., Peale, F., Deng, Y., Daemen, A., Forrest, W. F., Kwong, M., Hedehus, M., Hatzivassiliou, G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409653111 · Cited by 112
Current State of Our Knowledge on Brain Tumor Epidemiology
Ostrom, Q. T., & Barnholtz‐Sloan, J. S. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0189-8 · Cited by 112
Stieber, D., Golebiewska, A., Evers, L., Lenkiewicz, E., Brons, N. H. C., Nicot, N., Oudin, A., Bougnaud, S., Hertel, F., Bjerkvig, R., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1196-4 · Cited by 112
Sun, J., Masterman-Smith, M. D., Graham, N. A., Jiao, J., Mottahedeh, J., Laks, D. R., Ohashi, M., DeJesus, J., Kamei, K., Lee, K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0076 · Cited by 111
Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas
Welander, J., Larsson, C., Bäckdahl, M., Hareni, N., Sivlér, T., Brauckhoff, M., Söderkvist, P., & Gimm, O. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds402 · Cited by 112
Suppression of autophagy impedes glioblastoma development and induces senescence
Gammoh, N., Dudley-Fraser, J., Puente, C., Syred, H. M., Kang, H. H., Ozawa, T., Lam, D., Acosta, J. C., Finch, A. J., Holland, E. C., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1190053 · Cited by 114
EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells
Krusche, B., Ottone, C., Clements, M., Johnstone, E. R., Goetsch, K., Huang, L., Mota, S. G., Singh, P., Khadayate, S. P., Ashraf, A., et al. (2016) · eLife · doi:10.7554/elife.14845 · Cited by 114
Chang, N., Ahn, S. H., Kong, D., Lee, H. W., & Nam, D. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.004 · Cited by 117
Xu, L., Chen, Y., Mayakonda, A., Koh, L., Chong, Y. K., Buckley, D. L., Sandanaraj, E., Lim, S. W., Lin, R. Y., Ke, X., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712363115 · Cited by 112
Self-citationWang, W., Lu, Z., Wang, M., Liu, Z., Wu, B., Yang, C., He, H., & Gong, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.998236 · Cited by 114
A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells
Mao, D. D., Gujar, A. D., Mahlokozera, T., Chen, I., Pan, Y., Luo, J. R., Brost, T. M., Thompson, E. A., Turski, A., Leuthardt, E. C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.027 · Cited by 113
Quantification of Nanosized Extracellular Membrane Vesicles with Scanning Ion Occlusion Sensing
de Vrij, J., Maas, S. L. N., van Nispen, M., Sena‐Esteves, M., Limpens, R. W. A. L., Koster, A. J., Leenstra, S., Lamfers, M. L. M., & Broekman, M. L. D. (2013) · Nanomedicine · doi:10.2217/nnm.12.173 · Cited by 111
Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
Heiland, D. H., Haaker, G., Delev, D., Mercas, B., Masalha, W., Heynckes, S., Gaebelein, A., Pfeifer, D., Carro, M. S., Weyerbrock, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15031 · Cited by 113
Manda, S. V., Kataria, Y., Tatireddy, B. R., Ramakrishnan, B., Ratnam, B. G., Lath, R., Ranjan, A., & Ray, A. K. (2017) · Journal of neurosurgery · doi:10.3171/2016.11.jns161187 · Cited by 111
Establishment of age group classification for risk stratification in glioma patients
Lin, Z., Yang, R., Li, K., Yi, G., Li, Z., Guo, J., Zhang, Z., Junxiang, P., Liu, Y., Qi, S., et al. (2020) · BMC Neurology · doi:10.1186/s12883-020-01888-w · Cited by 114
USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance
Lee, J., Chang, N., Yoon, Y., Yang, H., Cho, H., Kim, E. H., Shin, Y., Kang, W., Oh, Y. T., Mun, G. I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov091 · Cited by 114
Choi, E. J., Cho, B. J., Lee, D., Hwang, Y., Chun, S. H., Kim, H. H., & Kim, I. A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-17 · Cited by 114
Preusser, M., Wöehrer, A., Stary, S., Höftberger, R., Streubel, B., & Hainfellner, J. A. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31822713f0 · Cited by 109
van den Bent, M. J., Gravendeel, L. A. M., Gorlia, T., Kros, J. M., Lapre, L., Wesseling, P., Teepen, J. L. J. M., Idbaïh, A., Sanson, M., Smitt, P. A. E. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1274 · Cited by 108
Culture conditions defining glioblastoma cells behavior: what is the impact for novel discoveries?
Ledur, P. F., Onzi, G. R., Zong, H., & Lenz, G. (2017) · Oncotarget · doi:10.18632/oncotarget.20193 · Cited by 106
A STAT3-based gene signature stratifies glioma patients for targeted therapy
Tan, M. S. Y., Sandanaraj, E., Chong, Y. K., Lim, S. W., Koh, L., Ng, W. H., Tan, N. S., Tan, P. B. O., Ang, B. T., & Tang, C. (2019) · Nature Communications · doi:10.1038/s41467-019-11614-x · Cited by 109
Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma
Grafals‐Ruiz, N., Ríos-Vicil, C. I., Lozada-Delgado, E. L., Quiñones‐Díaz, B. I., Rivera, R. A. N., Martínez-Zayas, G., Santana‐Rivera, Y., Santiago-Sánchez, G. S., Valiyeva, F., & Vivas‐Mejía, P. E. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s241055 · Cited by 111
Yin, Y., Rodriguez, J. L., Li, N., Thokala, R., Nasrallah, M. P., Hu, L., Zhang, L., Zhang, J. V., Logun, M. T., Kainth, D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.011 · Cited by 110
Comba, A., Faisal, S. M., Dunn, P., Argento, A. E., Hollon, T. C., Al‐Holou, W. N., Varela, M. L., Zamler, D. B., Quass, G. L., Apostolides, P. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31340-1 · Cited by 123
Integrated proteogenomic characterization of glioblastoma evolution
Kim, K., Migliozzi, S., Koo, H., Hong, J.-H., Park, S. M., Kim, S., Kwon, H. J., Ha, S., Garofano, L., Oh, Y. T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.015 · Cited by 123
Erdem‐Eraslan, L., Gravendeel, L. A. M., de Rooi, J., Eilers, P. H. C., Idbaïh, A., Spliet, W. G. M., den Dunnen, W. F. A., Teepen, J. L. J. M., Wesseling, P., Smitt, P. A. E. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1444 · Cited by 110
Reardon, D. A., Wen, P. Y., & Mellinghoff, I. K. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou232 · Cited by 111
Ge, H., Mu, L., Jin, L., Yang, C., Chang, Y. E., Yu, L., DeLeon, G., Deleyrolle, L. P., Mitchell, D. A., Kubilis, P. S., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30830 · Cited by 109
Chen, Q., Han, B. R., Meng, X., Duan, C., Yang, C., Wu, Z., Dinislam, M., Zhao, S., Safin, S. M., Jiang, C., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32102 · Cited by 110
Sa, J. K., Chang, N., Lee, H. W., Cho, H. J., Ceccarelli, M., Cerulo, L., Yin, J., Kim, S. S., Caruso, F. P., Lee, M., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02140-x · Cited by 108
Self-citationGlioblastoma Immune Landscape and the Potential of New Immunotherapies
Daubon, T., Hémadou, A., Garmendia, I. R., & Saleh, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585616 · Cited by 111
Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments
Gómez‐Oliva, R., Domínguez‐García, S., Carrascal, L., Ábalos-Martínez, J., Pardillo-Díaz, R., Verástegui, C., Castro, C., Nunez‐Abades, P., & Geribaldi‐Doldán, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.614295 · Cited by 114
Alexopoulos, L. G., Sáez-Rodríguez, J., Cosgrove, B. D., Lauffenburger, D. A., & Sorger, P. K. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.000406 · Cited by 113
Phillips, J. J., Aranda, D., Ellison, D. W., Judkins, A. R., Croul, S. E., Brat, D. J., Ligon, K. L., Horbinski, C., Venneti, S., Zadeh, G. M., et al. (2013) · Brain Pathology · doi:10.1111/bpa.12043 · Cited by 108
Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0192-4 · Cited by 108
Karsy, M. J., Gelbman, M., Shah, P., Balumbu, O., MOY, F. H., & Arslan, E. (2012) · Folia Neuropathologica · doi:10.5114/fn.2012.32361 · Cited by 109
REST Regulates Oncogenic Properties of Glioblastoma Stem Cells
Kamal, M. M., Sathyan, P., Singh, S. K., Zinn, P. O., Marisetty, A., Liang, S., Gumin, J., EL-Mesallamy, H. O., Suki, D., Colman, H., et al. (2012) · Stem Cells · doi:10.1002/stem.1020 · Cited by 108
Prognostic Value of a Nine‐Gene Signature in Glioma Patients Based on mRNA Expression Profiling
Bao, Z., Li, M., Wang, J., Zhang, C., Wang, H., Yan, W., Liu, Y., Zhang, W., Chen, L., & Jiang, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12171 · Cited by 108
Comprehensive analysis of microRNA expression profile in malignant glioma tissues
Piwecka, M., Rolle, K., Belter, A., Barciszewska, A. M., Żywicki, M., Michalak, M., Nowak, S., Naskręt-Barciszewska, M. Z., & Barciszewski, J. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.03.007 · Cited by 108
NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age
Gray, G. K., McFarland, B. C., Nozell, S. E., & Benveniste, E. N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.964211 · Cited by 109
Zinn, P. O., Singh, S. K., Kotrotsou, A., Hassan, I. S. A., Thomas, G. A., Luedi, M. M., Elakkad, A., Elshafeey, N. A., Idris, T., Mosley, J. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3420 · Cited by 108
GPD1 Specifically Marks Dormant Glioma Stem Cells with a Distinct Metabolic Profile
Rusu, P., Shao, C., Neuerburg, A., Acikgöz, A. A., Wu, Y., Zou, P., Phapale, P., Shankar, T. S., Döring, K., Dettling, S., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.06.004 · Cited by 108
Matarredona, E. R., & Pastor, Á. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00779 · Cited by 110
Cell Lineage-Based Stratification for Glioblastoma
Wang, Z., Sun, D., Chen, Y.-J., Xie, X., Shi, Y., Tabar, V. S., Brennan, C., Bale, T., Jayewickreme, C. D., Laks, D. R., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.003 · Cited by 106
Self-citationLe, N. Q. K., Hung, T. N. K., Do, D. T., Lam, L. H. T., Đăng, L. H., & Huynh, T.-T. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104320 · Cited by 108
Microvesicles as Mediators of Intercellular Communication in Cancer
Antonyak, M. A., & Cerione, R. A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0856-1_11 · Cited by 113
Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies
Masui, K., Cloughesy, T. F., & Mischel, P. S. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01238.x · Cited by 113
Recruited Brain Tumor‐Derived Mesenchymal Stem Cells Contribute to Brain Tumor Progression
Behnan, J., Isakson, P., Joel, M., Cilio, C., Langmoen, I. A., Vik-Mo, E. O., & Badn, W. (2013) · Stem Cells · doi:10.1002/stem.1614 · Cited by 107
Unraveling the molecular genetics of head and neck cancer through genome-wide approaches
Riaz, N., Morris, L. G. T., Lee, W., & Chan, T. A.-T. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.07.002 · Cited by 111
Chaddad, A. (2015) · International Journal of Biomedical Imaging · doi:10.1155/2015/868031 · Cited by 107
Prognostic relevance of epilepsy at presentation in glioblastoma patients
Berendsen, S., Varkila, M. R. J., Kroonen, J., Seute, T., Snijders, T. J., Kauw, F., Spliet, W. G. M., Willems, M., Poulet, C., Broekman, M. L. D., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov238 · Cited by 107
Levitin, H. M., Yuan, J., Cheng, Y. L., Ruiz, F. J. R., Bush, E. C., Bruce, J. N., Canoll, P., Iavarone, A., Lasorella, A., Blei, D. M., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188557 · Cited by 98
Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
Kan, L. K., Drummond, K. J., Hunn, M., Williams, D. J., O'Brien, T. J., & Monif, M. (2020) · BMJ Neurology Open · doi:10.1136/bmjno-2020-000069 · Cited by 109
Epigenomic Reprogramming as a Driver of Malignant Glioma
Phillips, R. E., Soshnev, A. A., & Allis, C. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.008 · Cited by 111
See, W. L., Tan, I., Mukherjee, J., Nicolaides, T. P., & Pieper, R. O. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0334 · Cited by 106
Omuro, A. M. P., Beal, K. P., Gutin, P. H., Karimi, S., Correa, D. D., Kaley, T. J., DeAngelis, L. M., Chan, T. A.-T., Gavrilovic, I. T., Nolan, C. P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0822 · Cited by 109
Self-citationAstrocytes enhance glioblastoma growth
Mega, A., Nilsen, M. H., Leiss, L. W., Tobin, N. P., Miletić, H., Sleire, L., Strell, C., Nelander, S., Krona, C. C., Hägerstrand, D., et al. (2019) · Glia · doi:10.1002/glia.23718 · Cited by 106
miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma
Mathew, L. K., Skuli, N., Mucaj, V., Lee, S. S., Zinn, P. O., Sathyan, P., Imtiyaz, H. Z., Zhang, Z., Davuluri, R. V., Rao, S. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314341111 · Cited by 105
Stangeland, B., Mughal, A. A., Grieg, Z., Sandberg, C. J., Joel, M., Nygård, S., Meling, T. R., Murrell, W. G., Vik-Mo, E. O., & Langmoen, I. A. (2015) · Oncotarget · doi:10.18632/oncotarget.4613 · Cited by 110
Song, F.-J., Yang, D., Liu, B., Guo, Y., Zheng, H., Li, L., Wang, T., Yu, J.-P., Zhao, Y., Niu, R.-F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1844 · Cited by 110
Genovese, G., Ergün, A., Shukla, S. A., Campos, B., Hanna, J. A., Ghosh, P., Quayle, S. N., Rai, K., Colla, S., Ying, H., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0111 · Cited by 106
Self-citationHarmonization of quality metrics and power calculation in multi-omic studies
Tarazona, S., Balzano-Nogueira, L., Gómez-Cabrero, D., Schmidt, A., Imhof, A., Hankemeier, T., Tegnér, J., Westerhuis, J. A., & Conesa, A. (2020) · Nature Communications · doi:10.1038/s41467-020-16937-8 · Cited by 105
Genetic, cellular, and connectomic characterization of the brain regions commonly plagued by glioma
Mandal, A. S., Romero-García, R., Hart, M. G., & Suckling, J. (2020) · Brain · doi:10.1093/brain/awaa277 · Cited by 104
Global mapping of cancers: The Cancer Genome Atlas and beyond
Ganini, C., Amelio, I., Bertolo, R. G., Bove, P., Buonomo, O. C., Candi, E., Cipriani, C., Daniele, N. D., Juhl, H. H., Mauriello, A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13056 · Cited by 110
Liang, W.-W., Lu, R. J.-H., Jayasinghe, R. G., Foltz, S. M., Porta-Pardo, E., Geffen, Y., Wendl, M. C., Lazcano, R., Kolodziejczak, I., Song, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.013 · Cited by 105
Self-citationLee, W., & Liu, Y. (2012) · Journal of Multivariate Analysis · doi:10.1016/j.jmva.2012.03.013 · Cited by 108
Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action
Lorente, M., Torres, S., Salazar‐Roa, M., Carracedo, A., Hernández‐Tiedra, S., Rodríguez-Fornés, F., García-Taboada, E., Meléndez, B., Mollejo, M., Campos‐Martín, Y., et al. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2010.170 · Cited by 108
Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience
Bezecny, P. (2014) · Medical Oncology · doi:10.1007/s12032-014-0985-5 · Cited by 107
Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege
Fecci, P. E., Heimberger, A. B., & Sampson, J. H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0832 · Cited by 105
Inhibition of Notch Signaling Blocks Growth of Glioblastoma Cell Lines and Tumor Neurospheres
Chen, J., Kesari, S., Rooney, C., Strack, P. R., Chen, J., Shen, H., Wu, L., & Griffin, J. D. (2010) · Genes & Cancer · doi:10.1177/1947601910383564 · Cited by 104
Clark, P. A., Bhattacharya, S., Elmayan, A., Darjatmoko, S. R., Thuro, B. A., Yan, M. B., van Ginkel, P. R., Polans, A. S., & Kuo, J. S. (2016) · Journal of neurosurgery · doi:10.3171/2016.1.jns152077 · Cited by 106
Shingu, T., Ho, A. L., Yuan, L., Zhou, X., Dai, C., Zheng, S., Wang, Q., Zhong, Y., Chang, Q., Horner, J. W., et al. (2016) · Nature Genetics · doi:10.1038/ng.3711 · Cited by 106
Self-citationGlutamine Addiction In Gliomas
Márquez, J., Alonso, F. J., Matés, J. M., Segura, J. A., Martín‐Rufián, M., & Campos-Sandoval, J. A. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2212-1 · Cited by 106
Patrizii, M., Bartucci, M., Pine, S. R., & Sabaawy, H. E. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00023 · Cited by 107
Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review
Kazerooni, A. F., Bakas, S., Rad, H. S., & Davatzikos, C. A. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26907 · Cited by 104
Eyler, C. E., Matsunaga, H., Hovestadt, V., Vantine, S. J., van Galen, P., & Bernstein, B. (2020) · Genome biology · doi:10.1186/s13059-020-02085-1 · Cited by 104
Masui, K., Gini, B., Wykosky, J., Zanca, C., Mischel, P. S., Furnari, F. B., & Cavenee, W. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt086 · Cited by 111
Phillips, J. J., Huillard, E., Robinson, A. E., Ward, A., Lum, D. H., Polley, M. C., Rosen, S. D., Rowitch, D. H., & Werb, Z. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58215 · Cited by 107
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Omuro, A. M. P., Chan, T. A.-T., Abrey, L. E., Khasraw, M., Reiner, A. S., Kaley, T. J., DeAngelis, L. M., Lassman, A. B., Nolan, C. P., Gavrilovic, I. T., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos295 · Cited by 101
Endothelial cells induce cancer stem cell features in differentiated glioblastoma cells via bFGF
Fessler, E., Borovski, T., & Medema, J. P. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0420-3 · Cited by 103
Unravelling tumour heterogeneity—implications for therapy
Reardon, D. A., & Wen, P. Y. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.223 · Cited by 106
Kamoun, A., Idbaïh, A., Dehais, C., Elarouci, N., Carpentier, C., Letouzé, É., Colin, C., Mokhtari, K., Jouvet, A., Uro‐Coste, E., et al. (2016) · Nature Communications · doi:10.1038/ncomms11263 · Cited by 104
Han, M., Xu, R., Wang, S., Yang, N., Ni, S., Zhang, Q. H., Xu, Y., Zhang, X., Zhang, C., Wei, Y., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.04.002 · Cited by 101
Metadata
- Authors
- Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H. S., Hodgson, J. G., James, C. D., Sarkaria, J. N., Brennan, C., Kahn, A., Spellman, P. T., Wilson, R. K., Speed, T. P., Gray, J. W., Meyerson, M., Getz, G., Perou, C. M., & Hayes, D. N.
- Affiliations
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Berkeley (US)
- Washington University in St. Louis (US)
- Lawrence Berkeley National Laboratory (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- SRA International (United States) (US)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Hayes, D. Neil
- ORCID
- Verhaak, Roel G.W.
- Hoadley, Katherine A.
- Purdom, Elizabeth
- Wang, Victoria
- Qi, Yuan
- Wilkerson, Matthew D.
- Miller, C. Ryan
- Ding, Li
- Golub, Todd
- Mesirov, Jill P.
- Lawrence, Michael
- Tamayo, Pablo
- Gabriel, Stacey
- Winckler, Wendy
- Gupta, Supriya
- Feiler, Heidi S.
- Hodgson, J. Graeme
- James, C. David
- Sarkaria, Jann N.
- Brennan, Cameron
- Spellman, Paul T.
- Wilson, Richard K.
- Speed, Terence P.
- Gray, Joe W.
- Meyerson, Matthew
- Getz, Gad
- Perou, Charles M.
- Hayes, D. Neil
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 17
- Issue
- 1
- Pages
- 98-110
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2818769
- OpenAlex
- W2161289668
- Cited by
- 7,575
- References
- 52
- Citations by year
- 2026: 312 · 2025: 399 · 2024: 451 · 2023: 551 · 2022: 523 · 2021: 697 · 2020: 593 · 2019: 493 · 2018: 482 · 2017: 522 · 2016: 502 · 2015: 455 · 2014: 459 · 2013: 406 · 2012: 379
- FWCI
- 159.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Energy
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (CA097257, L30 CA104183, U24CA126554, R01CA127716, CA108961, U24CA126546, U24CA126543, U24CA126563, U24CA126544, U24CA143867, U24CA143848, P50CA108961, U24CA126551, CA127716, P50 CA 58223, U24CA126561, P50CA058223, P50CA097257)
- National Institute of Neurological Disorders and Stroke (R01NS049720, NS49720)
- National Institute of Environmental Health Sciences (F30ES019449)
- National Center for Research Resources (RR023248, K12RR023248, UL1RR024992)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioblastoma, molecular subtypes, proneural subtype, mesenchymal subtype, classical subtype, PDGFRA, IDH1, EGFR, neurofibromatosis type 1, somatic mutations, gene expression signatures, neural lineage, treatment response, molecular stratification
- MeSH terms
- Adult, Aged, Brain Neoplasms, DNA Mutational Analysis, Factor Analysis, Statistical, Glioblastoma, Humans, Isocitrate Dehydrogenase, Middle Aged, Mutation, Neurofibromatosis 1, Prognosis, Gene Expression, Gene Dosage, Oligonucleotide Array Sequence Analysis, Receptor, Platelet-Derived Growth Factor alpha, Gene Expression Profiling, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
